For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Woolcock media release: "Powerful Inhaler Changes Lung Treatment in a SIngle Puff"Read full media release - pdf
Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland. Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of care.
Bronchitol is the first non-antibiotic therapy to be accepted by the SMC for the treatment of CF.
The recommendation enables Scottish adults that are in need of new treatment options for their CF, to gain access to Bronchitol. Bronchitol is accepted for use as an add-on to best standard of care, in adults who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and who have a rapidly declining lung function and in whom other osmotic agents are considered unsuitable.Read full media release - pdf
Pharmaceutical company Pharmaxis Ltd (ASX: PXS) today announced that the Company has elected to receive the full US$40 million allowed for under the Financing Agreement signed in January 2013 with NovaQuest Pharma Opportunities Fund III, LP (NovaQuest). The initial investment of US$20 million was made by NovaQuest in February 2013 and an additional US$20 million investment is subject to Pharmaxis meeting certain commercial and regulatory performance criteria including randomisation of the first patient into a US pivotal Phase 3 clinical trial by 17 October 2014.
Pharmaxis entered into the Financing Agreement with NovaQuest to ensure the Company had sufficient funds to pursue the US approval of Bronchitol for cystic fibrosis. Under the terms of the agreement the Company had nine months (until 29 October 2013) to advise NovaQuest if it wished to reduce the additional US$20 million investment. The Company has elected not to reduce the additional investment. Pharmaxis will receive the additional US$20 million investment after the first patient is randomised into the US pivotal Phase 3 clinical trial required by the US Food and Drug Administration to obtain approval of Bronchitol in the United States. The additional investment will be paid in four equal instalments of US$5 million, each three months apart.Read full media release - pdf